CVS says the decision to cover Wegovy and exclude Zepbound is "forcing the drug manufacturers to compete with one another" and will encourage both Eli Lilly and Novo Nordisk to lower prices for their ...

Some less expensive versions of popular weight loss drugs are no longer available to patients, after the Food & Drug ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

"Employers have absorbed the majority of cost increases over the past four years, and they likely cannot continue to do so," ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the drugmaker in a more vulnerable position when rival Eli Lilly ...

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

CVS Caremark will stop covering Eli Lilly's Zepbound, a weight loss drug, due to insurance company changes. Patients are outraged and concerned.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...